Traws Pharma, Inc. SEC filings TRAW
Traws Pharma, Inc. has 988 filings in SEC EDGAR's recent list, going back to Jan 8, 2003. Its latest annual report, Form ARS, was filed on May 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (material agreement, unregistered share sale). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Oct 20, 2026 | — |
| DEF 14A | Proxy statement | Oct 20, 2026 | Dec 3, 2026 |
| PRE 14A | Preliminary proxy statement | Oct 8, 2026 | Oct 8, 2026 |
| DEFA14A | Additional proxy material | May 29, 2026 | — |
| DEF 14A | Proxy statement | May 29, 2026 | Jul 8, 2026 |
| PRE 14A | Preliminary proxy statement | May 19, 2026 | May 19, 2026 |
| DEFA14A | Additional proxy material | Oct 8, 2025 | — |
| DEF 14A | Proxy statement | Oct 8, 2025 | Nov 21, 2025 |
| DEF 14A | Proxy statement | Feb 6, 2025 | Feb 17, 2025 |
| PRE 14A | Preliminary proxy statement | Jan 27, 2025 | Jan 27, 2025 |
| DEF 14A | Proxy statement | Oct 11, 2024 | Oct 31, 2024 |
| DEF 14A | Proxy statement | Aug 9, 2024 | Sep 16, 2024 |
| PRE 14A | Preliminary proxy statement | Jun 27, 2024 | Jun 27, 2024 |
| DEFA14A | Additional proxy material | Apr 16, 2024 | — |
| DEFA14A | Additional proxy material | Apr 4, 2024 | — |
| DEFA14A | Additional proxy material | Jul 21, 2023 | — |
| DEF 14A | Proxy statement | Jun 7, 2023 | Jul 21, 2023 |
| DEFA14A | Additional proxy material | Jul 21, 2022 | — |
| DEF 14A | Proxy statement | May 25, 2022 | Jul 21, 2022 |
| DEFA14A | Additional proxy material | Jul 16, 2021 | — |
| DEFA14A | Additional proxy material | Jun 25, 2021 | — |
| DEF 14A | Proxy statement | May 28, 2021 | Jun 25, 2021 |
| DEFA14A | Additional proxy material | Apr 1, 2021 | — |
| DEFA14A | Additional proxy material | Mar 29, 2021 | — |
| DEFA14A | Additional proxy material | Mar 29, 2021 | — |
| DEFA14A | Additional proxy material | Mar 11, 2021 | — |
| DEFA14A | Additional proxy material | Mar 8, 2021 | — |
| DEFA14A | Additional proxy material | Mar 4, 2021 | — |
| DEFA14A | Additional proxy material | Feb 26, 2021 | — |
| DEFA14A | Additional proxy material | Feb 19, 2021 | — |
| DEFA14A | Additional proxy material | Feb 3, 2021 | — |
| DEF 14A | Proxy statement | Jan 13, 2021 | Mar 4, 2021 |
| PRE 14A | Preliminary proxy statement | Dec 31, 2020 | Mar 4, 2021 |
| DEFA14A | Additional proxy material | Jun 12, 2020 | — |
| DEFA14A | Additional proxy material | Jun 10, 2020 | — |
| DEFA14A | Additional proxy material | Jun 2, 2020 | — |
| DEFA14A | Additional proxy material | May 11, 2020 | — |
| DEFA14A | Additional proxy material | May 11, 2020 | — |
| DEF 14A | Proxy statement | Apr 23, 2020 | May 27, 2020 |
| PRE 14A | Preliminary proxy statement | Apr 9, 2020 | May 27, 2020 |
| DEF 14A | Proxy statement | Apr 29, 2019 | Jun 17, 2019 |
| DEF 14A | Proxy statement | Jun 8, 2018 | Jun 27, 2018 |
| PRE 14A | Preliminary proxy statement | May 25, 2018 | Jun 27, 2018 |
| DEF 14A | Proxy statement | May 17, 2018 | Jun 7, 2018 |
| PRE 14A | Preliminary proxy statement | May 7, 2018 | Jun 7, 2018 |
| DEF 14A | Proxy statement | Feb 28, 2018 | Mar 21, 2018 |
| PRE 14A | Preliminary proxy statement | Feb 16, 2018 | Mar 21, 2018 |
| DEF 14A | Proxy statement | Apr 12, 2017 | May 17, 2017 |
| DEF 14A | Proxy statement | Apr 13, 2016 | May 18, 2016 |
| PRE 14A | Preliminary proxy statement | Apr 1, 2016 | May 18, 2016 |
| DEF 14A | Proxy statement | Apr 29, 2015 | Jun 15, 2015 |
| DEF 14A | Proxy statement | Apr 29, 2014 | May 22, 2014 |
Showing 52 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TRAW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newtown, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1130598
- Former names
- Onconova Therapeutics, Inc. (until Apr 1, 2024); ONCONOVA THERAPEUTICS INC (until May 26, 2009)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.